The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAnimalcare Grp Regulatory News (ANCR)

Share Price Information for Animalcare Grp (ANCR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 231.00
Bid: 224.00
Ask: 238.00
Change: 1.00 (0.43%)
Spread: 14.00 (6.25%)
Open: 230.00
High: 231.00
Low: 230.00
Prev. Close: 230.00
ANCR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of 2023 FY Results

25 Jan 2024 07:00

RNS Number : 8290A
Animalcare Group PLC
25 January 2024
 

ANIMALCARE GROUP PLC

 

(the "Company" or the "Group")

 

Trading Update and Notice of 2023 Full Year Results

 

25 January 2024. Animalcare Group plc (AIM: ANCR), the international animal health business, provides the following unaudited trading update for the year ended 31 December 2023. Preliminary unaudited results are expected to be published on 9 April 2024.

 

Trading overview

Animalcare is pleased to report growth in revenue and underlying EBITDA* in line with market expectations along with a further strengthening of the financial platform.

 

The Group returned to revenue growth in 2023 with sales increasing across all product segments and direct operations. Overall, full year revenues are expected to be approximately £74.4 million (2022: £71.6 million), an increase of c. 4.0% at AER (c. 2.0% at CER). Headline revenues benefited from strong growth in the Companion Animals oral health range, notably Plaqtiv+, demand for Danilon in Equine and continuing momentum of the Identicare pet microchipping and consumer-focused services business. Additionally, Daxocox recorded double-digit growth across Animalcare's direct sales territories.

 

The Group anticipates that underlying EBITDA will be in line with market expectations and at least in line with 2022 (2022: £13.1 million), reflecting a combination of strong gross margins and targeted SG&A investment, primarily on our people.

 

Continued strong cash generation, approximately in line with the rate delivered in 2022, further reinforced the balance sheet. The Group ended the financial year in a net cash position, pre IFRS16 leases, of £1.7 million, (31 December 2022: £2.4 million debt). This very strong financial platform enables the pursuit of inorganic and organic opportunities that support the Group's long-term growth strategy.

 

Jenny Winter, Chief Executive Officer commented: "I am delighted to deliver such a positive performance update for the full year which underlines our growing capability as well as the attractive fundamentals of the markets in which we operate. Our financial platform - stronger than ever - equips us with the firepower and flexibility to grow our business over the long term through investment in our people, our pipeline and external business development opportunities. That remains a key priority."

 

* The Group presents a number of non-GAAP Alternative Performance Measures (APMs) which exclude non-underlying items. EBITDA is defined as underlying earnings before interest, tax, depreciation and amortisation.

 

About Animalcare

Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organisation. Animalcare operates in seven countries and exports to approximately 40 countries in Europe and worldwide. The Group is focused on bringing new and innovative products to market through its own development pipeline, partnerships and via acquisition.

 

For more information about Animalcare, please visit www.animalcaregroup.com or contact:

 

Animalcare Group plc

Jenny Winter, Chief Executive Officer

Chris Brewster, Chief Financial Officer

Media/investor relations

 

+44 (0)1904 487 687

 

 

communications@animalcaregroup.com

 

Stifel Nicolaus Europe Limited (Nominated Adviser & Joint Broker)

Ben Maddison

Nick Adams

Nicholas Harland

 

+44 (0)20 7710 7600

Panmure Gordon

(Joint Broker)

Corporate Finance

Freddy Crossley/Emma Earl

Corporate Broking

Rupert Dearden

 

+44 (0)20 7886 2500

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTFLFLTLDISFIS
Date   Source Headline
12th Jul 202111:04 amRNSNotification of Major Holding
12th Jul 20217:00 amRNSExercise of options
9th Jul 20214:59 pmRNSNotification of Major Holding
9th Jul 20213:20 pmRNSNotification of Major Holding
8th Jul 20215:45 pmRNSResult of Secondary Placing
8th Jul 20214:41 pmRNSSecond Price Monitoring Extn
8th Jul 20214:35 pmRNSPrice Monitoring Extension
8th Jul 20212:06 pmRNSSecond Price Monitoring Extn
8th Jul 20212:00 pmRNSPrice Monitoring Extension
8th Jul 20211:00 pmRNSProposed Secondary Placing
1st Jul 20217:00 amRNSTotal Voting Rights
21st Jun 20217:00 amRNSExercise of options
17th Jun 202110:17 amRNSDirector/PDMR Notification
10th Jun 20214:41 pmRNSSecond Price Monitoring Extn
10th Jun 20214:35 pmRNSPrice Monitoring Extension
9th Jun 20215:03 pmRNSResult of 2021 AGM
17th May 20217:00 amRNSAnnual Report 2020 and Notice of AGM
22nd Apr 20217:00 amRNSDaxocox approved by EU and UK authorities
30th Mar 20217:00 amRNSFull Year Results 2020
23rd Mar 20217:00 amRNSNotification of major holding
18th Feb 20214:36 pmRNSPrice Monitoring Extension
18th Feb 20213:43 pmRNSDaxocox receives positive opinion from CVMP in EU
8th Feb 20212:46 pmRNSNotification of major holding
1st Feb 20217:00 amRNSAppointment of Nominated Advisor and Joint Broker
21st Jan 20217:00 amRNSTrading Update and Notice of Full Year Results
18th Nov 20207:00 amRNSGrant of options
29th Sep 20207:00 amRNSInterim Results H1 2020
28th Sep 20207:00 amRNSAnimalcare and Kane Biotech to target biofilms
23rd Jul 20207:00 amRNSTrading Update and Notice of Results
30th Jun 20204:00 pmRNSResult of AGM 2020
9th Jun 20203:55 pmRNS2019 Annual Report and Notice of 2020 AGM
28th May 20207:00 amRNSFull year results 2019
18th May 202011:20 amRNSNotice of Full Year 2019 Results
25th Mar 20207:00 amRNSTrading update, revised date for full year results
23rd Jan 20207:00 amRNSTrading Update & Notice of Results
17th Jan 20208:55 amRNSHoldings in Company
24th Sep 20197:00 amRNSHalf Year Results
25th Jul 20197:00 amRNSDirectorate Change
23rd Jul 20197:00 amRNSTrading Update & Notice of Results
16th Jul 201911:37 amRNSNotification of major holdings
25th Jun 20191:40 pmRNSResult of AGM
19th Jun 20193:52 pmRNSBoard change
10th Jun 20192:55 pmRNSDirector/PDMR Shareholding
22nd May 20197:00 amRNSAnnual Report and Notice of Annual General Meeting
8th May 201910:35 amRNSDividend Declaration
30th Apr 20197:00 amRNS2018 Full Year Results
21st Jan 20197:00 amRNSTrading Update and Notice of Results
30th Oct 20187:50 amRNSAdditional Listing
1st Oct 201812:45 pmRNSAdditional Listing
25th Sep 20185:36 pmRNSDividend Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.